8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) May 2, 2019

TELEFLEX INCORPORATED

(Exact name of Registrant as Specified in Its Charter)

Delaware	1-5353	23-1147939
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)

550 East Swedesford Road, Suite 400, Wayne, Pennsylvania		19087
(Address of Principal Executive Offices)		(Zip Code)
Registrant’s Telephone Number, Including Area Code	(610) 225-6800

Not applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered
	Common Stock, par value $1 per share	TFX	New York Stock Exchange

Item 2.02. Results of Operations and Financial Condition.

On May 2, 2019, Teleflex Incorporated (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2019. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report.

In addition to the financial information included in the Press Release that has been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), the Press Release includes certain non-GAAP financial measures. These measures include constant currency revenue growth and adjusted diluted earnings per share. Constant currency revenue growth is based upon net revenues, adjusted to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of fluctuations that do not reflect our underlying performance or business trends. Adjusted diluted earnings per share is based upon diluted earnings per share available to common stockholders, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact (net of tax) of (i) restructuring, restructuring related and impairment items; (ii) acquisition, integration and divestiture related items; (iii) other items identified in note (C) to each of the reconciliation tables set forth in the Press Release for the quarters ended March 31, 2019 and April 1, 2018; (iv) intangible amortization expense; and (v) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Management uses these non-GAAP financial measures to assess the Company's financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1 hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

Item 7.01. Regulation FD Disclosure.

In connection with the conference call to be held by the Company on May 2, 2019 to discuss its financial results for the quarter ended March 31, 2019, the Company plans to reference a slide presentation, which will be made available in advance of the call through the Company’s website. A copy of the slide presentation is furnished as Exhibit 99.2 to this Current Report.

The information furnished pursuant to Item 7.01 of this Current Report, including Exhibit 99.2, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1Earnings Press Release, dated May 2, 2019

99.2Earnings Conference Call Slide Presentation

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 2, 2019 TELEFLEX INCORPORATED By: /s/ Thomas E. Powell Name: Thomas E. Powell Title: Executive Vice President and             Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Earnings Press Release, dated May 2, 2019
99.2	Earnings Conference Call Slide Presentation

EX-99.1

Exhibit 99.1

Jake Elguicze  Treasurer and Vice President of Investor Relations   610-948-2836

FOR IMMEDIATE RELEASE May 2, 2019

TELEFLEX REPORTS FIRST QUARTER 2019 RESULTS

First Quarter Revenues from Continuing Operations of $613.6 million, up 4.5% versus Prior Year Period; up 7.6% on a Constant Currency Basis

First Quarter GAAP Diluted EPS from Continuing Operations of $0.89, down 24.6% versus Prior Year Period

First Quarter Adjusted Diluted EPS from Continuing Operations of $2.24, up 4.2% versus Prior Year Period

Reaffirmed 2019 Guidance Range for GAAP Revenue Growth of between 5% and 6%

Reaffirmed 2019 Guidance Range for Constant Currency Revenue Growth of between 6% and 7%

Lowered 2019 Guidance Range for GAAP Diluted EPS from Continuing Operations from a range of between $6.90 and $7.05 to a range of between $6.72 and $6.84

Reaffirmed 2019 Guidance Range for Adjusted Diluted EPS from Continuing Operations of between $10.90 and $11.10

Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2019.

First quarter 2019 net revenues were $613.6 million, an increase of 4.5% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues increased 7.6% over the year ago period.

First quarter 2019 GAAP earnings per share from continuing operations decreased 24.6% to $0.89, as compared to GAAP earnings per share of $1.18 in the prior year period. First quarter 2019 adjusted diluted earnings per share from continuing operations increased 4.2% to $2.24, compared to $2.15 in the prior year period.

Liam Kelly, President and Chief Executive Officer, said, “The first quarter of 2019 was an outstanding start to the

year for Teleflex. We reported constant currency revenue growth of 7.6%, placing us in a strong position to achieve our full year constant currency revenue growth guidance range of between 6% and 7%. From a product perspective, our robust top line performance in the quarter was led by sales of our Interventional Urology, OEM, and Interventional products. While from a geographic standpoint, we achieved particularly strong growth within Asia and the Americas. In addition, during the quarter we continued to invest in driving the adoption of our high-growth, high-margin products, which puts us on track to deliver on both our near, and long-term, financial objectives.”

FIRST QUARTER NET REVENUE BY SEGMENT

The following table provides information regarding net revenues in each of the Company's reportable operating segments for the three months ended March 31, 2019 on both a GAAP and constant currency basis. The discussion below the table of the principal factors behind changes in net revenues for the three months ended March 31, 2019 as compared to the prior year period applies to both GAAP revenue and constant currency revenue, although GAAP revenue also was affected by foreign currency exchange rate fluctuations, as indicated in the "Currency Impact" column of the table.

	Three Months Ended				% Increase / (Decrease)
	March 31, 2019		April 1, 2018		Total Sales Growth			Currency Impact			Constant Currency Revenue Growth
Americas	$	344.0	$	323.3	6.4		%	(0.3	)	%	6.7	%
EMEA		154.6		159.9	(3.3	)	%	(7.8	)	%	4.5	%
Asia		60.8		58.2	4.3		%	(6.7	)	%	11.0	%
OEM		54.2		45.8	18.3		%	(1.8	)	%	20.1	%
Total	$	613.6	$	587.2	4.5		%	(3.1	)	%	7.6	%

Americas first quarter 2019 net revenues were $344.0 million, an increase of 6.4% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues increased 6.7% compared to the prior year period. The increase in constant currency revenue is primarily attributable to an increase in sales volumes of existing products and an increase in new product sales.

EMEA first quarter 2019 net revenues were $154.6 million, a decrease of 3.3% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues increased 4.5% compared to the prior year period. The increase in constant currency revenue is primarily attributable to an increase in sales volumes of existing products.

Asia first quarter 2019 net revenues were $60.8 million, an increase of 4.3% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues increased

11.0% compared to the prior year period. The increase in constant currency revenue is primarily attributable to an increase in sales volumes of existing products and an increase in new product sales.

OEM first quarter 2019 net revenues were $54.2 million, an increase of 18.3% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues increased 20.1% compared to the prior year period. The increase in constant currency revenue is primarily attributable to higher sales volumes of existing products.

FIRST QUARTER NET REVENUE BY GLOBAL PRODUCT CATEGORY

The following table and commentary provides information regarding net revenues in each of the Company's global product categories for the three months ended March 31, 2019 on both a GAAP and constant currency basis.

	Three Months Ended				% Increase / (Decrease)
	March 31, 2019		April 1, 2018		Total Sales Growth			Currency Impact			Constant Currency Revenue Growth
Vascular Access	$	143.9	$	144.0	(0.1	)	%	(2.6	)	%	2.5		%
Interventional		103.2		90.1	14.5		%	(2.6	)	%	17.1		%
Anesthesia		80.3		84.9	(5.5	)	%	(4.0	)	%	(1.5	)	%
Surgical		86.7		85.6	1.3		%	(3.7	)	%	5.0		%
Interventional Urology		59.7		42.3	41.2		%	(0.3	)	%	41.5		%
OEM		54.2		45.8	18.3		%	(1.8	)	%	20.1		%
Other		85.6		94.4	(9.3	)	%	(4.2	)	%	(5.1	)	%
Total	$	613.6	$	587.2	4.5		%	(3.1	)	%	7.6		%

First quarter 2019 net revenues from sales of Vascular Access products were $143.9 million, a decrease of 0.1% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues increased 2.5% compared to the prior year period.

First quarter 2019 net revenues from sales of Interventional products were $103.2 million, an increase of 14.5% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues increased 17.1% compared to the prior year period.

First quarter 2019 net revenues from sales of Anesthesia products were $80.3 million, a decrease of 5.5% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues decreased 1.5% compared to the prior year period.

First quarter 2019 net revenues from sales of Surgical products were $86.7 million, an increase of 1.3% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues increased 5.0% compared to the prior year period.

First quarter 2019 net revenues from sales of Interventional Urology products were $59.7 million, an increase of 41.2% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues increased 41.5% compared to the prior year period.

First quarter 2019 net revenues from sales of OEM products were $54.2 million, an increase of 18.3% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues increased 20.1% compared to the prior year period.

First quarter 2019 net revenues from sales of Other products were $85.6 million, a decrease of 9.3% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, first quarter 2019 net revenues decreased 5.1% compared to the prior year period.

OTHER FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE METRICS

Depreciation expense, amortization of intangible assets and deferred financing charges for the first three months of 2019 totaled $54.6 million compared to $53.8 million for the prior year period.

Cash and cash equivalents at March 31, 2019 were $271.2 million compared to $357.2 million at December 31, 2018.

Net accounts receivable at March 31, 2019 were $375.8 million compared to $366.3million at December 31, 2018.

Net inventories at March 31, 2019 were $445.6 million compared to $427.8million at December 31, 2018.

2019 OUTLOOK

On a GAAP basis, revenues in 2019 are expected to increase between 5% and 6% over the prior year, reflecting our estimate of an approximately 1% unfavorable impact of foreign currency exchange rate fluctuations. On a constant currency basis, the Company estimates that revenues for full year 2019 will increase between 6% and 7%.

The Company lowered its full year 2019 GAAP diluted earnings per share from continuing operations guidance from a range of between $6.90 and $7.05 to a range of between $6.72 and $6.84, reflecting the impact of additional restructuring, contingent consideration, intangible amortization expenses, and tax adjustments. The Company expects adjusted diluted earnings per share from continuing operations to be between $10.90 and $11.10 for full year 2019, representing an increase of between 10.1% and 12.1% over 2018, and reflecting our estimate of an approximately 2% negative impact from foreign currency exchange rate fluctuations.

Forecasted 2019 Constant Currency Revenue Growth Reconciliation

	Low		High
Forecasted 2019 GAAP revenue growth	5.0	%	6.0	%
Estimated impact of foreign currency exchange rate fluctuations	(1.0)%		(1.0)%
Forecasted 2019 constant currency revenue growth	6.0	%	7.0	%

Forecasted 2019 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation

	Low			High
Forecasted GAAP diluted earnings per share from continuing operations		$6.72			$6.84
Restructuring, restructuring related and impairment items, net of tax		$0.83			$0.86
Acquisition, integration and divestiture related items, net of tax		$0.83			$0.85
Other items, net of tax		$0.11			$0.12
Intangible amortization expense, net of tax		$2.62			$2.64
Tax adjustments		($0.21	)		($0.21	)
Forecasted adjusted diluted earnings per share from continuing operations		$10.90			$11.10

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION

As previously announced, Teleflex will comment on its financial results on a conference call to be held today at 8:00 a.m. (ET). The call will be available live and archived on the company’s website at www.teleflex.comand the accompanying presentation will be posted prior to the call. An audio replay will be available until May 7, 2019 at 11:00pm (ET), by calling 855-859-2056 (U.S./Canada) or 404-537-3406 (International), Passcode: 6798477.

ADDITIONAL NOTES

References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.

In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.

Certain financial information is presented on a rounded basis, which may cause minor differences.

Segment results and commentary exclude the impact of discontinued operations.

NOTES ON NON-GAAP FINANCIAL MEASURES

We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP.” In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: constant currency revenue growth and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

Tables reconciling changes in historical constant currency net revenues to historical GAAP net revenues are set forth above under “First Quarter Net Revenue by Segment." Tables reconciling historical adjusted diluted earnings per share from continuing operations to historical GAAP diluted earnings per share from continuing operations are set forth below. Tables reconciling forecasted 2019 constant currency revenue growth and forecasted 2019 adjusted earnings per share from continuing operations to their respective most directly comparable forecasted GAAP measures, forecasted 2019 GAAP revenue growth and forecasted 2019 GAAP diluted earnings per share from continuing operations, respectively, are set forth above under “2019 Outlook.”

Constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Restructuring, restructuring related and impairment items -Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on

the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program.  Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions.  These charges may include, among other things, professional, consulting and other fees; systems integration costs; legal entity restructuring expense; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales.  Depending primarily on the terms of the divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

Other items -These are discrete items that occur sporadically and can affect period-to-period comparisons. See footnote C to the reconciliation tables set forth below.

Intangible amortization expense -Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

Tax adjustments -These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law changes affecting our deferred tax liability.

RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS

Dollars in millions, except per share amounts

Quarter Ended - March 31, 2019
	Cost of goods sold		Selling, general and administrative expenses		Research and development expenses		Restructuring and impairment charges	(Gain)/Loss on sale of businesses & assets			Income taxes		Income (loss) from continuing operations		Diluted earnings per share from continuing operations
GAAP Basis	$	268.8	$	227.7	$	27.2	$17.4	$	2.7	)	$	11.0	$	41.9	$	0.89
Adjustments
Restructuring, restructuring related and impairment items (A)	3.0		0.0		0.0		17.4	—			1.9		18.5		$	0.39
Acquisition, integration and divestiture related items (B)	—		13.6		—		—	(2.7)			(1.9)		12.7		$	0.27
Other items (C)	—		1.3		—		—	—			0.3		1.0		$0.02
Intangible amortization expense	—		37.6		0.1		—	—			7.7		30.0		$	0.64
Tax adjustments	—		—		—		—	—			(0.7)		0.7		$0.01
Adjusted basis	$	265.8	$	175.2	$	27.0	—	—			$	18.3	$	105.0	$	2.24

RECONCILIATION OF CONSOLIDATED STATEMENT OF INCOME ITEMS

Dollars in millions, except per share amounts

Quarter Ended - April 1, 2018
	Cost of goods sold			Selling, general and administrative expenses		Research and development expenses		Restructuring and impairment charges	Income taxes			Income (loss) from continuing operations			Diluted earnings per share from continuing operations
GAAP Basis	$	256.0		$	215.3	$	26.0	$3.1	$	6.2		$	54.9		$	1.18
Adjustments
Restructuring, restructuring related and impairment items (A)	2.0			0.1		0.1		3.1	0.7			4.5			$	0.10
Acquisition, integration and divestiture related items (B)	0.4			11.5		0.2		—	0.5			11.5			$	0.25
Other items (C)	(1.0		)	0.1		—		—	(0.1		)	(0.7		)	$	0.02	)
Intangible amortization expense	—			37.7		0.1		—	7.6			30.3			$	0.65
Tax adjustments	—			—		—		—	(0.2		)	0.2			$0.00
Adjusted basis	$	254.6		$	165.9	$	25.7	—	$	14.7		$	100.6		$	2.15

(A) Restructuring, restructuring related and impairment items -For the three months ended March 31, 2019, pre-tax restructuring charges were $14.4 million, pre-tax restructuring related charges were $3.1 million, and pre-tax impairment charges were $3.0 million. For the three months ended April 1, 2018, pre-tax restructuring charges were $3.1 million and pre-tax restructuring related charges were $2.1 million. There were no impairment items during the three months ended April 1, 2018.

(B) Acquisition, integration and divestiture related items -For the three months ended March 31, 2019, these charges primarily related to contingent consideration liabilities and our acquisition of NeoTract, somewhat offset by the gain on sale of a divested business. For the three months ended April 1, 2018, these charges primarily related to contingent consideration liabilities and our acquisition of NeoTract.  There were no divestiture related activities for the three months ended April 1, 2018.

(C) Other items - For the three months ended March 31, 2019, other items included expenses associated with a franchise tax audit, relabeling costs, and costs associated with European Medical Device Regulation initiatives.  For the three months ended April 1, 2018, other items included the reversal of previously recognized income due to distributor acquisitions related to Vascular Solutions, and relabeling costs. 

ABOUT TELEFLEX INCORPORATED

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow^®, Deknatel^®, Hudson RCI^®, LMA^®, Pilling^®, Rusch^®, UroLift^®, and Weck^® - trusted brands united by a common sense of purpose.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, our expectation that our continued investment in driving the adoption of our high-growth, high-margin products puts us on track to deliver on both our near and long-term financial objectives; forecasted 2019 GAAP and constant currency revenue growth and GAAP and adjusted diluted earnings per share; and our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2019 financial results. Actual results could differ materially from those in the forward-looking statements due to, among other things, changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; the inability of acquired businesses to generate revenues in accordance with our expectations; our inability to effectively execute our restructuring programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend or replace the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, sovereign debt issues and the impact of the United Kingdom's pending departure from the European

Union; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

	Three Months Ended
	March 31, 2019			April 1, 2018
	(Dollars and shares in thousands, except per share)
Net revenues	$	613,584		$	587,230
Cost of goods sold	268,842			255,960
Gross profit	344,742			331,270
Selling, general and administrative expenses	227,693			215,337
Research and development expenses	27,150			26,027
Restructuring and impairment charges	17,395			3,063
Gain on sale of assets	(2,739		)	—
Income from continuing operations before interest and taxes	75,243			86,843
Interest expense	22,692			25,943
Interest income	(339		)	(273		)
Income from continuing operations before taxes	52,890			61,173
Taxes on income from continuing operations	10,972			6,242
Income from continuing operations	41,918			54,931
Operating income (loss) from discontinued operations	(1,343		)	1,235
Benefit on income (loss) from discontinued operations	(322		)	(18		)
Income (loss) from discontinued operations	(1,021		)	1,253
Net income	$	40,897		$	56,184
Earnings per share:
Basic:
Income from continuing operations	$	0.91		$	1.21
Income (loss) from discontinued operations	(0.02		)	0.03
Net income	$	0.89		$	1.24
Diluted:
Income from continuing operations	$	0.89		$	1.18
Income (loss) from discontinued operations	(0.02		)	0.02
Net income	$	0.87		$	1.20
Dividends per share	$	0.34		$	0.34
Weighted average common shares outstanding
Basic	46,050			45,329
Diluted	46,942			46,695

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

	March 31, 2019		December 31, 2018
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	271,212	$	357,161
Accounts receivable, net of allowances of $9,225 and $9,348, respectively	375,756		366,286
Inventories, net	445,566		427,778
Prepaid expenses and other current assets	79,595		72,481
Prepaid taxes	10,485		12,463
Total current assets	1,182,614		1,236,169
Property, plant and equipment, net	409,963		432,766
Operating lease assets	112,278		—
Goodwill	2,247,768		2,246,579
Intangible assets, net	2,274,488		2,325,052
Deferred tax assets	2,500		2,446
Other assets	38,458		34,979
Total assets	$	6,268,069	$	6,277,991
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	86,625	$	86,625
Accounts payable	103,532		106,709
Accrued expenses	93,649		97,551
Current portion of contingent consideration	99,686		136,877
Payroll and benefit-related liabilities	76,261		104,670
Accrued interest	23,245		6,031
Income taxes payable	6,641		5,943
Other current liabilities	31,277		38,050
Total current liabilities	520,916		582,456
Long-term borrowings	2,072,939		2,072,200
Deferred tax liabilities	610,606		608,221
Pension and postretirement benefit liabilities	89,287		92,914
Noncurrent liability for uncertain tax positions	10,833		10,718
Noncurrent contingent consideration	80,676		167,370
Noncurrent operating lease liabilities	100,708		—
Other liabilities	212,226		204,134
Total liabilities	3,698,191		3,738,013
Commitments and contingencies
Total shareholders' equity	2,569,878		2,539,978
Total liabilities and shareholders' equity	$	6,268,069	$	6,277,991

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended
	March 31, 2019			April 1, 2018
	(Dollars in thousands)
Cash flows from operating activities of continuing operations:
Net income	$	40,897		$	56,184
Adjustments to reconcile net income to net cash provided by operating activities:
(Income) loss from discontinued operations	1,021			(1,253		)
Depreciation expense	15,645			14,832
Amortization expense of intangible assets	37,751			37,816
Amortization expense of deferred financing costs and debt discount	1,179			1,178
Gain on sale of assets	(2,739		)	—
Changes in contingent consideration	13,057			9,592
Asset impairment	3,030			—
Stock-based compensation	5,781			4,787
Deferred income taxes, net	2,603			(1,472		)
Payments for contingent consideration	(25,935		)	—
Other	654			(1,272		)
Changes in assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(14,102		)	(3,402		)
Inventories	(19,200		)	32
Prepaid expenses and other assets	(11,524		)	(3,406		)
Accounts payable, accrued expenses and other liabilities	8,856			(27,185		)
Income taxes receivable and payable, net	3,192			417
Net cash provided by operating activities from continuing operations	60,166			86,848
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(23,494		)	(15,747		)
Proceeds from sale of assets	991			—
Payments for businesses and intangibles acquired, net of cash acquired	(1,025		)	(3,684		)
Net cash used in investing activities from continuing operations	(23,528		)	(19,431		)
Cash flows from financing activities of continuing operations:
Reduction in borrowings	—			(18,500		)
Debt extinguishment, issuance and amendment fees	—			(74		)
Net proceeds from share based compensation plans and the related tax impacts	2,242			1,400
Payments for contingent consideration	(110,953		)	(91		)
Dividends paid	(15,650		)	(15,447		)
Net cash provided by (used in) financing activities from continuing operations	(124,361		)	(32,712		)
Cash flows from discontinued operations:
Net cash used in operating activities	3,610			(206		)
Net cash used in discontinued operations	3,610			(206		)
Effect of exchange rate changes on cash and cash equivalents	(1,836		)	10,815
Net (decrease) increase in cash and cash equivalents	(85,949		)	45,314
Cash and cash equivalents at the beginning of the period	357,161			333,558
Cash and cash equivalents at the end of the period	$	271,212		$	378,872
Non cash financing activities of continuing operations:
Acquisition of treasury stock associated with settlement and exchange of convertible note hedge and warrant agreements	$	—		$	17,872

EX-99.2

Teleflex Incorporated First Quarter 2019 Earnings Conference Call 1

Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on “Investors”) Telephone replay available by dialing (855) 859-2056 or for international calls, (404) 537-3406, pass code number 6798477 2

Today’s Speakers Liam Kelly President and CEO Thomas Powell Executive Vice President and CFO Jake Elguicze Treasurer and Vice President, Investor Relations 3

Note on Forward-Looking Statements This presentation and our discussion contain forward-looking information and statements including, but not limited to, forecasted 2019 GAAP and constant currency revenue growth, GAAP and adjusted gross and operating margins, GAAP and adjusted earnings per share and the items that are expected to impact each of those forecasted results; our assumptions with respect to the euro to U.S. dollar exchange rate for 2019 and our adjusted weighted average shares for 2019; estimated pre-tax charges we expect to incur in connection with our ongoing restructuring programs; estimated annualized pre-tax savings we expect to realize in connection with our ongoing restructuring programs and a similar initiative within our OEM segment (the “OEM initiative”); our expectations with respect to when we will begin to realize savings from our ongoing restructuring programs and the OEM initiative and when those programs will be substantially completed; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward–looking statements. These risks and uncertainties are addressed in our SEC filings, including our most recent Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation. Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures, including, but not limited to, constant currency revenue growth, adjusted diluted earnings per share, adjusted gross and operating margins and adjusted tax rate. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Tables reconciling these non-GAAP financial measures to the most comparable GAAP financial measures are contained within this presentation and the appendices at the end of this presentation. Additional Notes This document contains certain highlights with respect to our first 2019 performance and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended March 31, 2018 located in the investor section of our website at www.teleflex.com and our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission. Unless otherwise noted, the following slides reflect continuing operations. 4

1Q19 Highlights Revenue Highlights • As-reported revenue increased 4.5% versus 1Q18 • Constant currency revenue increased 7.6% versus 1Q18 • Reaffirmed full year 2019 as-reported and constant currency revenue growth guidance ranges Broad Based Product Category and Geographic Performance1 • Interventional Urology revenues of $59.7 million, up 41.5% over 1Q18 as UroLift® continues strong momentum • OEM revenues of $54.2 million, up 20.1% over 1Q18, driven by catheters and performance fiber products • Interventional revenues of $103.2 million, up 17.1% over 1Q18, driven by intra-aortic products, catheters, biologics and On-Control® • Asia revenues of $60.8 million, up 11% over 1Q18 driven by Surgical, Vascular and Interventional product categories Adjusted Margin and Adjusted EPS Highlights • Adjusted gross margin of 56.7%, up 10 bps versus 1Q18 • Adjusted operating margin of 23.7%, down 30 bps versus 1Q18 • Adjusted EPS of $2.24, up 4.2% versus 1Q18 • Reaffirmed full year 2019 adjusted gross margin, operating margin and earnings per share guidance ranges 1. All global product family revenue growth provided is on a constant currency basis Note: See appendices for reconciliations of non-GAAP information 5

Segment Revenue Review Total Constant Dollars Q1’19 Q1’18 Currency Sales Currency in Millions Revenue Revenue Impact Growth Growth Americas $344.0 $323.3 6.4% (0.3%) 6.7% EMEA $154.6 $159.9 (3.3%) (7.8%) 4.5% Asia $60.8 $58.2 4.3% (6.7%) 11.0% OEM $54.2 $45.8 18.3% (1.8%) 20.1% TOTAL $613.6 $587.2 4.5% (3.1%) 7.6% 6

Global Product Category Revenue Review Total Constant Dollars Q1’19 Q1’18 Currency Sales Currency in Millions Revenue Revenue Impact Growth Growth Vascular Access $143.9 $144.0 (0.1%) (2.6%) 2.5% Interventional $103.2 $90.1 14.5% (2.6%) 17.1% Anesthesia $80.3 $84.9 (5.5%) (4.0%) (1.5%) Surgical $86.7 $85.6 1.3% (3.7%) 5.0% Interventional Urology $59.7 $42.3 41.2% (0.3%) 41.5% OEM $54.2 $45.8 18.3% (1.8%) 20.1% Other1 $85.6 $94.4 (9.3%) (4.2%) (5.1%) TOTAL $613.6 $587.2 4.5% (3.1%) 7.6% 1. Includes revenues generated from sales of the Company’s respiratory and urology products. 7

Product and Clinical Updates UroLift® System Real-World Clinical Presentations at 2019 American Urological Association, Chicago KEY TAKEAWAYS Presentations on Saturday May 4th, 2019 • “Real World Outcomes of Prostatic Urethral Lift Confirm Clinical Study Results” to be presented by Steven Gange, M.D., Summit Urology Group, Salt Lake City, at 10:30 a.m. CT in room 185a • “Prostatic Urethral Lift (PUL) Symptom and Sexual Function Results Maintained in the Treatment of All Types of Prostate Enlargement Including Obstructive Middle Lobe” to be presented by Daniel Rukstalis, M.D., Wake Forest University School of Medicine, at 10:40 a.m. CT in room 185a UroLift® System UroLift® System • “Early Outcomes of Prostate Urethral Lift in Subjects Permanent Implant Delivery Device Acute Urinary Retention” to be presented by Mark Rochester, M.D., Norwich University Hospital, at 10:50 a.m. CT in room 185a • “Prostatic Urethral Lift (PUL) and Magnetic Resonance Imaging (MRI): Defining artefact and risk of obscuring significant cancer” to be presented by Peter Chin, M.B.B.S., Wollongong University Graduate School of Medicine, Australia, at 3:30 p.m. CT in room 178ab 8

1Q19 Financial Review Revenue of $613.6 million • Up 4.5% vs. prior year period on an as-reported basis • Up 7.6% vs. prior year period on a constant currency basis Gross Margin • GAAP gross margin of 56.2%, down 20 bps vs. prior year period • Adjusted gross margin of 56.7%, up 10 bps vs. prior year period Operating Margin • GAAP operating margin of 12.3%, down 250 bps vs. prior year period • Adjusted operating margin of 23.7%, down 30 bps vs. prior year period Tax Rate • GAAP tax rate of 20.7%, compared to 10.2% in the prior year period • Adjusted tax rate of 14.8%, compared to 12.8% in the prior year period Earnings per Share • GAAP EPS of $0.89, compared to $1.18 in the prior year period • Adjusted EPS of $2.24, up 4.2.% vs. prior year period 9 Note: See appendices for reconciliations of non-GAAP information

2019 Financial Outlook 2019 Revenue Guidance • Reaffirmed as-reported revenue growth guidance range of between 5% and 6% • Reaffirmed constant currency revenue growth guidance range of between 6% and 7% 2019 Gross Margin Guidance • Reaffirmed GAAP gross margin guidance range of between 57.2% and 57.75% • Reaffirmed adjusted gross margin guidance range of between 58.0% and 58.5% 2019 Operating Margin Guidance • Lowered GAAP operating margin guidance from a range of between 17.4% and 18.1% to a range of between 17.2% and 17.9% • Reaffirmed adjusted operating margin guidance range of between 26.5% to 27.0% 2019 Earnings per Share Guidance • Lowered GAAP EPS guidance from a range of between $6.90 and $7.05 to a range of between $6.72 and $6.84 • Reaffirmed adjusted earnings per share guidance range of between $10.90 and $11.10 10 Note: See appendices for reconciliations of non-GAAP information

Question and Answer Section 11

THANK YOU 12

Appendices 13

Non-GAAP Financial Measures The presentation to which these appendices are attached and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure: • Constant currency revenue growth. This non-GAAP measure is based upon net revenues, adjusted to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends. • Adjusted diluted earnings per share. This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items; (ii) acquisition, integration and divestiture related items; (iii) “other items” identified in note (C) to the reconciliation tables appearing in Appendices D and E; (iv) intangible amortization expense; and (v) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends. • Adjusted gross profit and margin. These measures exclude, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items, (ii) acquisition, integration and divestiture related items and (iii) “other items” identified in note (C) to the reconciliation table appearing in Appendix A. • Adjusted operating profit and margin. These measures exclude, depending on the period presented, the impact of (i) restructuring, restructuring related and impairment items; (ii) acquisitions, integration and divestiture related items; (iii) “other items” identified in note (C) to the reconciliation table appearing in Appendix B; and (iv) intangible amortization expense. • Adjusted tax rate. This measure is the percentage of the Company’s adjusted taxes on income from continuing operations to its adjusted income from continuing operations before taxes. Adjusted taxes on income from continuing operations excludes, depending on the period presented, the impact of tax benefits or costs associated with (i) restructuring, restructuring related and impairment items; (ii) acquisition, integration and divestiture related items; (iii) “other items” identified in note (A) to the reconciliation table appearing in Appendix C; (iv) intangible amortization expense; and (v) tax adjustments. 14

Non-GAAP Adjustments The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non- GAAP financial measures that appear in the presentation to which these appendices are attached: Restructuring, restructuring related and impairment items. Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program. Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, as a result of periodic impairment testing or due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results. Acquisition, integration and divestiture related items. Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; legal entity restructuring expense; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of the divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities. Other items. These are discrete items that occur sporadically and can affect period-to-period comparisons. Intangible amortization expense. Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions. Tax adjustments. These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law changes affecting our deferred tax liability. 15

Appendix A – Reconciliation of Adjusted Gross Profit and Margin Dollars in Thousands Three Months Ended March 31, 2019 April 1, 2018 Teleflex gross profit as-reported $ 344,742 $ 331,270 Teleflex gross margin as-reported 56.2% 56.4% Restructuring, restructuring related and impairment items (A) 3,013 1,959 Acquisition, integration and divestiture related items (B) - 352 Other items (C) - (983) Adjusted Teleflex gross profit $ 347,755 $ 332,598 Adjusted Teleflex gross margin 56.7% 56.6% Teleflex revenue as-reported $ 613,584 $ 587,230 (A) Restructuring, restructuring related and impairment items – The charges for all periods presented are for restructuring-related activities. (B) Acquisition, integration and divestiture related items – For the three months ended April 1, 2018, these charges primarily related to our acquisition of NeoTract. (C) Other items – For the three months ended April 1, 2018, other items included the reversal of previously recognized income due to distributor acquisitions related to Vascular Solutions. 16 See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions.

Appendix B – Reconciliation of Adjusted Operating Profit and Margin Dollars in Thousands Three Months Ended March 31, 2019 April 1, 2018 Teleflex income from continuing operations before interest, loss on extinguishment of debt and taxes $ 75,243 $ 86,843 Teleflex income from continuing operations before interest, loss on extinguishment of debt and taxes margin 12.3% 14.8% Restructuring, restructuring related and impairment items (A) 20,475 5,142 Acquisition, integration and divestiture related items (B) 10,834 12,033 Other items (C) 1,294 (838) Intangible amortization expense 37,751 37,816 Adjusted Teleflex income from continuing operations before interest, loss on extinguishment of debt and taxes $ 145,597 $ 140,996 Adjusted Teleflex income from continuing operations before interest, loss on extinguishment of debt and taxes margin 23.7% 24.0% Teleflex revenue as-reported $ 613,584 $ 587,230 (A) Restructuring, restructuring related and impairment items - For the three months ended March 31, 2019, pre-tax restructuring charges were $14.4 million, pre-tax restructuring related charges were $3.1 million, and pre-tax impairment charges were $3.0 million. For the three months ended April 1, 2018, pre-tax restructuring charges were $3.1 million and pre-tax restructuring related charges were $2.1 million. There were no impairment items during the three months ended April 1, 2018. (B) Acquisition, integration and divestiture related items - For the three months ended March 31, 2019, these charges primarily related to contingent consideration liabilities and our acquisition of NeoTract, somewhat offset by the gain on sale of a divested business. For the three months ended April 1, 2018, these charges primarily related to contingent consideration liabilities and our acquisition of NeoTract. There were no divestiture related activities for the three months ended April 1, 2018. (C) Other items - For the three months ended March 31, 2019, other items included expenses associated with a franchise tax audit, relabeling costs, and costs associated with European Medical Device Regulation initiatives. For the three months ended April 1, 2018, other items included the reversal of previously recognized income due to distributor acquisitions related to Vascular Solutions, and relabeling costs. 17 See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions.

Appendix C – Reconciliation of Adjusted Tax Rate Dollars in Thousands Teleflex Incorporated GAAP to Non-GAAP Tax Rate Reconciliation Three Months Ended Income from Taxes on continuing income from operations continuing before taxes operations Tax rate March 31, 2019 GAAP basis $52,890 $10,972 20.7% Restructuring, restructuring related and impairment charges $20,475 $1,933 Acquisition, integration and divestiture related items $10,834 ($1,907) Other items (A) $1,294 $250 Intangible amortization expense $37,751 $7,707 Tax adjustment $0 ($701) March 31, 2019 Adjusted basis $123,244 $18,254 14.8% April 1, 2018 GAAP basis $61,173 $6,242 10.2% Restructuring, restructuring related and impairment charges $5,142 $690 Acquisition, integration and divestiture related items $12,033 $522 Other items (A) ($838) ($115) Intangible amortization expense $37,816 $7,559 Tax adjustment $0 ($158) April 1, 2018 Adjusted basis $115,326 $14,740 12.8% (A) Other items - For the three months ended March 31, 2019, other items included expenses associated with a franchise tax audit, relabeling costs and costs associated with European Medical Device Regulation initiatives. For the three months ended April 1,2018, other items included the reversal of previously recognized income due to distributor acquisitions related to Vascular Solutions, and relabeling costs. 18 See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions.

Appendix D – Reconciliation of Adjusted EPS from Continuing Operations Three Months Ended– March 31, 2019 Dollars in Millions, except per share data Three Months Ended March 31, 2019 Selling, general Restructuring Diluted earnings Cost of Research and (Gain) loss on and and Income Income (loss) from per share from goods development sale of business administrative impairment taxes continuing operations continuing sold expenses and assets expenses charges operations GAAP Basis $268.8 $227.7 $27.2 $17.4 ($2.7) $11.0 $41.9 $0.89 Adjustments Restructuring, restructuring related and 3.0 0.0 0.0 17.4 — 1.9 18.5 $0.39 impairment items (A) Acquisition, integration and divestiture related — 13.6 — — (2.7) (1.9) 12.7 $0.27 items (B) Other items (C) — 1.3 — — — 0.3 1.0 $0.02 Intangible amortization — 37.6 0.1 — — 7.7 30.0 $0.64 expense Tax adjustments — — — — — (0.7) 0.7 $0.01 Adjusted basis $265.8 $175.2 $27.0 — — $18.3 $105.0 $2.24 19 See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions.

Appendix E – Reconciliation of Adjusted EPS from Continuing Operations Three Months Ended – April 1, 2018 Dollars in Millions, except per share data Three Months Ended April 1, 2018 Selling, general Restructuring Diluted earnings Cost of Research and and and Income Income (loss) from per share from goods development administrative impairment taxes continuing operations continuing sold expenses expenses charges operations GAAP Basis $256.0 $215.3 $26.0 $3.1 $6.2 $54.9 $1.18 Adjustments Restructuring, restructuring related and 2.0 0.1 0.1 3.1 0.7 4.5 $0.10 impairment items (A) Acquisition, integration and divestiture related 0.4 11.5 0.2 — 0.5 11.5 $0.25 items (B) Other items (C) (1.0) 0.1 — — (0.1) (0.7) ($0.02) Intangible amortization — 37.7 0.1 — 7.6 30.3 $0.65 expense Tax adjustments — — — — (0.2) 0.2 $0.00 Adjusted basis $254.6 $165.9 $25.7 — $14.7 $100.6 $2.15 20 See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions.

Appendices D and E – tickmarks (A) Restructuring, restructuring related and impairment items - For the three months ended March 31, 2019, pre-tax restructuring charges were $14.4 million, pre-tax restructuring related charges were $3.1 million, and pre-tax impairment charges were $3.0 million. For the three months ended April 1, 2018, pre-tax restructuring charges were $3.1 million and pre-tax restructuring related charges were $2.1 million. There were no impairment items during the three months ended April 1, 2018. (B) Acquisition, integration and divestiture related items - For the three months ended March 31, 2019, these charges primarily related to contingent consideration liabilities and our acquisition of NeoTract, somewhat offset by the gain on sale of a divested business. For the three months ended April 1, 2018, these charges primarily related to contingent consideration liabilities and our acquisition of NeoTract. There were no divestiture related activities for the three months ended April 1, 2018. (C) Other items - For the three months ended March 31, 2019, other items included expenses associated with a franchise tax audit, relabeling costs, and costs associated with European Medical Device Regulation initiatives. For the three months ended April 1, 2018, other items included the reversal of previously recognized income due to distributor acquisitions related to Vascular Solutions, and relabeling costs. 21 See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions.

Appendix F - Reconciliation of 2019 Revenue Guidance 2019 Guidance Low High Forecasted GAAP Revenue Growth 5.0% 6.0% Estimated impact of foreign currency exchange rate fluctuations (1.0%) (1.0%) Forecasted Constant Currency Revenue Growth 6.0% 7.0% 22

Appendix G – Reconciliation of 2019 Adjusted Gross and Operating Margin Guidance 2019 Guidance Low High Forecasted GAAP Gross Margin 57.20% 57.75% Estimated restructuring, restructuring related and impairment items 0.80% 0.75% Estimated acquisition, integration and divestiture related items 0.00% 0.00% Estimated other items 0.00% 0.00% Forecasted Adjusted Gross Margin 58.00% 58.50% 2019 Guidance Low High Forecasted GAAP Operating Margin 17.20% 17.90% Estimated restructuring, restructuring related and impairment items 1.75% 1.70% Estimated acquisition, integration and divestiture related items 1.45% 1.40% Estimated other items 0.25% 0.20% Estimated intangible amortization expense 5.85% 5.80% Forecasted Adjusted Operaitng Margin 26.50% 27.00% 23

Appendix H – Reconciliation of 2019 Adjusted Earnings Per Share Guidance 2019 Guidance Low High Forecasted GAAP Diluted Earnings Per Share $6.72 $6.84 Estimated Restructuring, restructuring related and impairment items, net of tax $0.83 $0.86 Estimated acquisition, integration and divestiture related items, net of tax $0.83 $0.85 Estimated other items, net of tax $0.11 $0.12 Estimated intangible amortization expense, net of tax $2.62 $2.64 Tax adjustments ($0.21) ($0.21) Forecasted Adjusted Diluted Earning Per Share $10.90 $11.10 24

Appendix I – 2019 Financial Outlook Assumptions Euro to U.S. Dollar exchange rate assumed to be approximately 1.15 for full year 2019 Adjusted weighted average shares expected to be approximately 47.2 million for full year 2019 2019 Calendar of shipping days: Q1’19 vs. Q1’18: no difference Q2’19 vs. Q2’18: 1 less day Q3’19 vs. Q3’18: no difference Q4’19 vs. Q4’18: 1 additional day FY’19 vs. FY’18: no difference 25

Appendix J – Teleflex Restructuring and Similar Cost Savings Initiatives Summary In February 2019, we initiated a restructuring plan primarily involving the relocation of certain manufacturing operations to existing lower-cost locations and related workforce reductions (the “2019 Footprint realignment plan"). These actions are expected to be substantially completed during 2022. We estimate that we will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2019 Footprint realignment plan of $56 million to $70 million, of which, we expect $21 million to $26 million to be incurred in 2019 and most of the balance is expected to be incurred prior to the end of 2021. We estimate that $53 million to $66 million of these charges will result in cash outlays, of which, $8 million to $9 million is expected to be made in 2019 and most of the balance is expected to be made by the end of 2021. Additionally, we expect to incur $29 million to $35 million in aggregate capital expenditures under the plan, of which, $18 million to $22 million is expected to be incurred during 2019 and most of the balance is expected to be incurred by the end of 2021. We expect to begin realizing plan-related savings in 2021 and expect to achieve annual pre-tax savings of $12 million to $14 million once the plan is fully implemented, which will benefit all of our segments except OEM. In addition to the 2019 Footprint realignment plan, we have ongoing restructuring programs related to the consolidation of our manufacturing operations (referred to as our 2018 and 2014 Footprint realignment plans). We also have similar ongoing activities to relocate certain manufacturing operations within our OEM segment (the "OEM initiative") that do not meet the criteria for a restructuring program under applicable accounting guidance; nevertheless, the activities should result in cost savings (we expect only minimal costs to be incurred in connection with the OEM initiative). With respect to our currently ongoing restructuring programs and the OEM initiative, the table below summarizes charges to be incurred and estimated annual pre-tax savings to be realized as follows: (1) with respect to charges (a) the estimated total charges that will be incurred once the restructuring programs and OEM initiative are completed; (b) the charges incurred through December 31, 2018; and (c) the estimated charges to be incurred from January 1, 2019 through the last anticipated completion date of the restructuring programs and OEM initiative and (2) with respect to estimated annual pre-tax savings, (a) the estimated total annual pre-tax savings to be realized once the restructuring programs and OEM initiative are completed; (b) the estimated annual pre-tax savings realized based on the progress of the restructuring programs and OEM initiative through December 31, 2018; and (c) the estimated additional annual pre-tax savings to be realized from January 1, 2019 through the last anticipated completion date of the restructuring programs and the OEM initiative. Estimated charges and pre-tax savings are subject to change based on, among other things, the nature and timing of restructuring activities and similar activities, changes in the scope of restructuring programs and the OEM initiative, unanticipated expenditures and other developments, the effect of additional acquisitions or dispositions, the failure to realize anticipated savings from a supply contract related to a component included in certain kits sold by our Americas segment and other factors that were not reflected in the assumptions made by management in previously estimating restructuring and restructuring related charges and estimated pre-tax savings. Moreover, estimated pre-tax savings constituting efficiencies with respect to increased costs that otherwise would have resulted from business acquisitions involve, among other things, assumptions regarding the cost structure and integration of businesses that previously were not administered by our management, which are subject to a particularly high degree of risk and uncertainty. It is likely that estimates of charges and pre-tax savings will change from time to time, and the table below reflects changes from amounts previously estimated. In addition, the table below does not include estimated charges and pre-tax savings related to substantially completed programs. For example, the 2017 Vascular Solutions integration program, the 2017 EMEA program, the 2016 Footprint realignment plan and the Other 2016 restructuring programs are excluded from the table below because they were substantially completed as of March 31, 2019. Additional details including estimated charges expected to be incurred in connection with the restructuring programs are described in Note 5 to the condensed consolidated financial statements included in this report. Pre-tax savings also can be affected by increases or decreases in sales volumes generated by the businesses subject to the consolidation of manufacturing operations; such variations in revenues can increase or decrease pretax savings generated by the consolidation of manufacturing operations. For example, an increase in sales volumes generated by the affected businesses, although likely increasing manufacturing costs, may generate additional savings with respect to costs that otherwise would have been incurred if the manufacturing operations were not consolidated. Actuals through Estimated remaining from January 1, 2019 through Dollars in Millions Estimated Total December 31, 2018 December 31, 2026 Restructuring charges $95 to $114 $68 $27 to $46 Restructuring related charges 1 $110 to $141 $34 $76 to $107 Total charges $205 to $255 $102 $103 to $153 OEM initiative annual pre-tax savings $6 to $7 $1 $5 to $6 Ongoing restructuring programs pre-tax $63 to $73 $21 $42 to $52 savings 2 Total annual pre-tax savings $69 to $80 $22 $47 to $58 1. Restructuring related charges represent costs that are directly related to the programs and principally constitute costs to transfer manufacturing operations to existing lower-cost locations, project management costs and accelerated depreciation, as well as a charge that is expected to be imposed by a taxing authority as a result of our exit from facilities in the authority's jurisdiction. Most of these charges (other than the tax charge) are expected to be recognized as cost of goods sold. 2. Substantially all the pre-tax savings are expected to result in reductions to cost of goods sold. As previously disclosed, during 2016, in connection with our execution of the 2014 Footprint realignment plan, we implemented changes to medication delivery devices included in certain of our kits, which are expected to result in increased product costs (and therefore reduce the annual savings we anticipated at the inception of the program). However, we also expect to achieve improved pricing on these kits that will offset the increased costs, resulting in estimated annual increased revenues of $3 million to $4 million, which is not reflected in the table above. Since 2017, we have realized an aggregate benefit of $2.4 million resulting from this incremental pricing. More recently, during the fourth quarter of 2017, we entered into an agreement with an alternate provider for the development and supply of a component to be included in certain kits sold by our Americas segment. The agreement will result in increased development costs but is expected to reduce the cost of the component supply, once the supply becomes commercially available, as compared to the costs incurred with respect to our current suppliers. Therefore, we anticipate a net savings from the agreement, which is reflected in the table above. 26